A5087055974- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Melanoma and MAPK Pathways
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- HER2/EGFR in Cancer Research
- Musculoskeletal synovial abnormalities and treatments
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Bone Tumor Diagnosis and Treatments
- CAR-T cell therapy research
- Neurofibromatosis and Schwannoma Cases
- Cancer Genomics and Diagnostics
- Nanoparticle-Based Drug Delivery
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Soft tissue tumor case studies
- Lymphoma Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Chronic Myeloid Leukemia Treatments
- Gastric Cancer Management and Outcomes
- Immunotherapy and Immune Responses
Vanderbilt University Medical Center
2015-2024
Vanderbilt University
2011-2022
Vanderbilt-Ingram Cancer Center
2011-2022
Breast Cancer Research Foundation
2014-2022
Tennessee Oncology
2010-2021
Merrimack Pharmaceuticals (United States)
2021
Dana-Farber Cancer Institute
2008-2021
University Hospitals Seidman Cancer Center
2018
Cleveland Clinic
2018
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2018
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, other connective tissues. The evaluation treatment patients with requires multidisciplinary team demonstrated expertise in the management these tumors. complete NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) for Tissue Sarcoma provide recommendations diagnosis, evaluation,...
Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in most tenosynovial giant-cell tumors. This observation has led to discovery and clinical development therapy targeting CSF1 receptor (CSF1R).Using x-ray co-crystallography guide our drug-discovery research, we generated a potent, selective CSF1R inhibitor, PLX3397, that traps kinase autoinhibited conformation. We then conducted multicenter, phase trial two parts analyze this compound. In first part, evaluated escalations...
An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely direction to ASCO's membership following publication or presentation potentially practice-changing data from major studies. This PCO addresses the utility using epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer (NSCLC) predict benefit taking a first-line EGFR tyrosine kinase inhibitor (TKI).Patients EGFR-mutated NSCLC have significantly...
Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. In this multicenter phase I trial (NCT01781429), 135 patients were enrolled to accelerated 3 + dose-escalation cohort six distinct dose-expansion cohorts. Dose escalation included 27 patients, dosed from 10 900 mg twice daily established the recommended II dose (RP2D) of 600 daily. exposure was proportional RP2D, which provided near-complete inhibition ERK whole blood....
Purpose BRAF V600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma much less commonly glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor , patients with gliomas that harbor this mutation. Patients Methods The VE-BASKET study was an open-label, nonrandomized, multicohort for -mutant nonmelanoma cancers. received vemurafenib 960 mg twice per day continuously until disease progression,...
The NCCN Guidelines for Soft Tissue Sarcoma provide recommendations the diagnosis, evaluation, treatment, and follow-up patients with soft tissue sarcomas. These Insights summarize panel discussion behind recent important updates to guidelines, including development of a separate distinct guideline gastrointestinal stromal tumors (GISTs); reconception management desmoid tumors; inclusion further diagnosis extremity/body wall, head/neck sarcomas, retroperitoneal sarcomas; modification...
Purpose Palifosfamide is the active metabolite of ifosfamide and does not require prodrug activation, thereby avoiding generation toxic metabolites. The PICASSO III trial compared doxorubicin plus palifosfamide with placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma. Patients Methods were randomly assigned 1:1 to receive 75 mg/m2 intravenously day 1 150 mg/m2/d days 3 or once every 21 up six cycles. primary end point was progression-free...
Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression IGF-1R seems to be crucial for this effect. We investigated the safety efficacy combination antibody cixutumumab mTOR inhibitor temsirolimus in patients with chemotherapy-refractory bone soft-tissue sarcomas according immunohistochemistry.We undertook a multicentre, open-label, phase 2 study 19 cancer centres USA. Patients aged at least 16...
Abstract Background. Oncogenic genetic alterations “drive” neoplastic cell proliferation. Small molecule inhibitors and antibodies are being developed that target an increasing number of these altered gene products. Next-generation sequencing (NGS) is a powerful tool to identify tumor-specific changes. To determine the clinical impact extensive analysis, we reviewed our experience using targeted NGS platform (FoundationOne) in advanced cancer patients. Patients Methods. We retrospectively...
PurposeTenosynovial giant cell tumor (TGCT), a rare locally aggressive neoplasm of the synovium joints and tendon sheaths, is associated with joint destruction, inflammation, pain, swelling, in part due to colony-stimulating factor 1 receptor–bearing macrophages recruited by genetic elevation activity. The most common treatment surgery, although promising pharmacologic treatments are development. Patient-reported outcome (PRO) instruments critical end points demonstrating clinical relevance...
First Page
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout gastrointestinal tract. Most these caused by oncogenic activating mutations in KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations diagnosis, evaluation, treatment, and follow-up patients with tumors. These Insights summarize panel discussion behind recent important updates to guidelines, including revised systemic therapy options unresectable, progressive,...
Abstract Purpose: HER3 is a key dimerization partner for other HER family members, and its expression associated with poor prognosis. This first-in-human study of U3-1287 (NCT00730470), fully human anti-HER3 monoclonal antibody, evaluated safety, tolerability, pharmacokinetics in patients advanced solid tumor. Experimental Design: The was conducted 2 parts: part 1—sequential cohorts received escalating doses (0.3–20 mg/kg) every weeks, starting 3 weeks after the first dose; 2—additional 9,...
PURPOSE To study whether BRAF V600 mutations in non–small-cell lung cancer (NSCLC) may indicate sensitivity to the inhibitor vemurafenib, we included a cohort of patients with NSCLC vemurafenib basket (VE-BASKET) study. On basis observed early clinical activity, expanded NSCLC. We present results from this cohort. METHODS This open-label, histology-independent, phase II six prespecified cohorts, including NSCLC, and seventh all-comers Patients received (960 mg two times per day) until...
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study solid tumors resulted the selection of 75 mg once daily dose besylate formulation molibresib as recommended Phase 2 (RP2D). Here we present results Part our study, investigating safety, pharmacokinetics, pharmacodynamics and clinical activity at RP2D for nuclear testis carcinoma (NC), cell lung cancer, castration-resistant prostate cancer (CRPC), triple-negative...
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, other connective tissues. The evaluation treatment patients with requires multidisciplinary team demonstrated expertise in the management these tumors. complete NCCN Guidelines for provide recommendations diagnosis, evaluation, extremity/superficial trunk/head neck STS, as well...
Tumors with neomorphic mutations in IDH1/2 have defective homologous recombination repair, resulting sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The Olaparib Combination trial is a phase II, open-label study which patients solid tumors harboring were treated olaparib as monotherapy, objective response and clinical benefit rates the primary end points.Ten IDH1/2-mutant by next-generation sequencing 300 mg twice daily.Three of five chondrosarcomas had benefit, including one...
Abstract Background Larotrectinib, a first‐in‐class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions. This subset analysis focuses on the safety of larotrectinib an expanded cohort TRK fusion sarcomas. Methods Patients (≥18 years old) sarcomas fusions were identified from three clinical trials. received 100 mg orally twice daily. Response was investigator‐assessed per...
For non-small cell lung cancer (NSCLC) patients with pN2 status, the use of postoperative radiotherapy (PORT) remains controversial. Here, we investigated association between different clinicopathological features and therapy local control survival in resected NSCLC.We retrospectively analyzed 83 NSCLC who underwent resection at Vanderbilt University Medical Center 1994 2004. The relationship 10 prognostic factors-gender, age diagnosis, histology, tumor size, number nodal stations involved,...